Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation

Cell Cycle

Volumn 11, Issue 11, 2012, Pages 2084-2091

  Moreth, Kristin ^a   Iozzo, Renato V ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biglycan; Decorin; Inflammasome; Macrophage; Micro RNA 21; PDCD4; Sepsis; TGF ; Toll like receptor; Tumor

Indexed keywords

BIGLYCAN; DECORIN; PROTEOGLYCAN; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; SMALL LEUCINE RICH PROTEOGLYCAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; INFLAMMATION; INNATE IMMUNITY; PROTEIN INTERACTION; REVIEW;

EID: 84861871896     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20316     Document Type: Review

References (73)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-20; PMID:20303872; http://dx.doi.org/10.1016/j.cell.2010.01.022.
2. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10:826-37; PMID:21088683; http://dx.doi.org/10. 1038/nri2873.
3. Ronald PC, Beutler B. Plant and animal sensors of conserved microbial signatures. Science 2010; 330:1061-4; PMID:21097929; http://dx.doi.org/10.1126/ science.1189468.
4. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-50; PMID:21616434; http://dx.doi.org/10.1016/j.immuni.2011.05.006.
5. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007; 76:447-80; PMID:17328678; http://dx.doi.org/10.1146/annurev.biochem.76.060605.122847.
6. McDonald B, Kubes P. Cellular and molecular choreography of neutrophil recruitment to sites of sterile inflammation. J Mol Med (Berl) 2011; 89:1079-88; PMID:21751029; http://dx.doi.org/10.1007/s00109-011-0784-9.
7. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011; 11:807-22; PMID:22094985.
8. Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 2010; 120:4251-72; PMID:21084753; http://dx.doi.org/10.1172/JCI42213.
9. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010; 10:501-13; PMID:20577267; http://dx.doi.org/10. 1038/nri2787.
10. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11:163-75; PMID:21331081; http://dx.doi.org/10.1038/nri2957.
11. Trinchieri G. Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts. Annu Rev Immunol 2012; 30:677-706; PMID:22224761; http://dx.doi.org/10.1146/annurev-immunol-020711-075008.
12. Schaefer L, Iozzo RV. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 2012; 22:56-7; PMID:22326829; http://dx.doi.org/10.1016/j.gde.2011.12.002.
13. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279-89; PMID:18340345; http://dx.doi.org/10.1038/nri2215.
14. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Tolllike receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-33; PMID:16025156; http://dx.doi.org/10.1172/JCI23755.
15. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 2009; 284:24035-48; PMID:19605353; http://dx.doi.org/10.1074/jbc.M109.014266.
16. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 2011; 4:75; PMID:22087031; http://dx.doi.org/10.1126/scisignal.2001868.
17. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; In Press.
18. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol 2010; 10:185-90; PMID:20045380; http://dx.doi.org/10.1016/j.coph.2009.11.007.
19. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 2011; 22:1200-7; PMID:21719787; http://dx.doi.org/10.1681/ASN. 2010050570.
20. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111; PMID:11781369; http://dx.doi.org/10.1084/jem. 20001858.
21. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457:102-6; PMID:19122641; http://dx.doi.org/10.1038/ nature07623.
22. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15:774-80; PMID:19561617; http://dx.doi.org/10.1038/nm.1987.
23. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-9; PMID:11994480.
24. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10:712-23; PMID:20865019; http://dx.doi.org/10.1038/nri2852.
25. Wu B, Huan T, Gong J, Zhou P, Bai Z. Domain combination of the vertebrate-like TLR gene family: implications for their origin and evolution. J Genet 2011; 90:401-8; PMID:22227927.
26. Inohara C, Chamaillard, McDonald C, Nuñez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74:355-83; PMID:15952891; http://dx.doi.org/10.1146/annurev.biochem.74.082803. 133347.
27. Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 2010; 277:3864-75; PMID:20840584; http://dx.doi.org/10.1111/j.1742-4658. 2010.07797.x.
28. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 2008; 283:21305-9; PMID:18463092; http://dx.doi.org/10.1074/jbc.R800020200.
29. Brandan E, Cabello-Verrugio C, Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 2008; 27:700-8; PMID:18694824; http://dx.doi.org/10.1016/ j.matbio.2008.07.004.
30. Merline R, Schaefer RM, Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal 2009; 3:323-35; PMID:19809894; http://dx.doi.org/10.1007/s12079-009-0066-2.
31. Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res 2010; 339:237-46; PMID:19513755; http://dx.doi.org/10.1007/s00441-009-0821-y.
32. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 2010; 29:248-53; PMID:20080181; http://dx.doi.org/10.1016/j.matbio.2010.01.001.
33. Young MF, Bi Y, Ameye L, Xu T, Wadhwa S, Heegaard A, et al. Small leucine-rich proteoglycans in the aging skeleton. J Musculoskelet Neuronal Interact 2006; 6:364-5; PMID:17185826.
34. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999; 274:4489-92; PMID:9988678; http://dx.doi.org/10.1074/jbc.274.8.4489.
35. Schönherr E, Sunderkötter C, Iozzo RV, Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 2005; 280:15767-72; PMID:15701628; http://dx.doi.org/10.1074/jbc.M500451200.
36. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, et al. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am J Pathol 2007; 170:301-15; PMID:17200203; http://dx.doi.org/10.2353/ajpath.2007. 060497.
37. Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, et al. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 2009; 60:5-13; PMID:20083846.
38. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, et al. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 2011; 286:34712-21; PMID:21840990; http://dx.doi.org/10.1074/jbc.M111.262766.
39. Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 2009; 185:743-54; PMID:19433454; http://dx.doi.org/10.1083/jcb.200901129.
40. Khan GA, Girish GV, Lala N, Di Guglielmo GM, Lala PK. Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol Endocrinol 2011; 25:1431-43; PMID:21659473; http://dx.doi.org/10.1210/me.2010- 0426.
41. Goldoni S, Iozzo RV. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 2008; 123:2473-9; PMID:18798267; http://dx.doi.org/10.1002/ijc.23930.
42. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011; 15:1013-31; PMID:21155971; http://dx.doi.org/10.1111/j.1582-4934.2010.01236.x.
43. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 1998; 101:406-12; PMID:9435313; http://dx.doi.org/10. 1172/JCI846.
44. Schaefer L, Macakova K, Raslik I, Micegova M, Gröne HJ, Schönherr E, et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002; 160:1181-91; PMID:11891213; http://dx.doi.org/10.1016/S0002-9440(10)64937-1.
45. Schaefer L, Beck KF, Raslik I, Walpen S, Mihalik D, Micegova M, et al. Biglycan, a nitric oxideregulated gene, affects adhesion, growth and survival of mesangial cells. J Biol Chem 2003; 278:26227-37; PMID:12719420; http://dx.doi.org/10.1074/jbc.M210574200.
46. Chen XD, Bian X, Teslovich TM, Stephan DA, Young MF. Dissection of the sets of genes that control the behavior of biglycan-deficient pre-osteoblasts using oligonucleotide microarrays. Bone 2005; 37:192-203; PMID:15922682; http://dx.doi.org/10.1016/j.bone.2005.04.006.
47. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 1990; 38:1549-63; PMID:2212616; http://dx.doi.org/10.1177/38.11.2212616.
48. Monfort J, Tardif G, Reboul P, Mineau F, Roughley P, Pelletier JP, et al. Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Res Ther 2006; 8:26; PMID:16507124; http://dx.doi.org/10.1186/ar1873.
49. Boukpessi T, Menashi S, Camoin L, Tencate JM, Goldberg M, Chaussain-Miller C. The effect of stromelysin-1 (MMP-3) on non-collagenous extracellular matrix proteins of demineralized dentin and the adhesive properties of restorative resins. Biomaterials 2008; 29:4367-73; PMID:18760468; http://dx.doi.org/10.1016/j.biomaterials.2008.07.035.
50. Calabrese GC, Gazzaniga S, Oberkersch R, Wainstok R. Decorin and biglycan expression: its relation with endothelial heterogeneity. Histol Histopathol 2011; 26:481-90; PMID:21360441.
51. Scott IC, Imamura Y, Pappano WN, Troedel JM, Recklies AD, Roughley PJ, et al. Bone morphogenetic protein-1 processes probiglycan. J Biol Chem 2000; 275:30504-11; PMID:10896944; http://dx.doi.org/10.1074/jbc.M004846200.
52. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720-32; PMID:21304099; http://dx.doi.org/10.1182/blood-2010-07-273417.
53. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S, et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998; 20:78-82; PMID:9731537; http://dx.doi.org/10.1038/ 2477.
54. Wang S, Schmaderer C, Kiss E, Schmidt C, Bonrouhi M, Porubsky S, et al. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88-and TRIF-dependent signaling. Dis Model Mech 2010; 3:92-103; PMID:20038715; http://dx.doi.org/10.1242/dmm.003533.
55. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117:2847-59; PMID:17853945; http://dx.doi.org/10.1172/JCI31008.
56. Leemans JC, Butter LM, Pulskens WP, Teske GJ, Claessen N, van der Poll T, et al. The role of Tolllike receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS One 2009; 4:5704; PMID:19479087; http://dx.doi.org/10.1371/journal.pone.0005704.
57. Anders HJ, Schlöndorff D. Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 2007; 16:177-83; PMID:17420659; http://dx.doi.org/10.1097/MNH.0b013e32803fb767.
58. Bedke J, Kiss E, Schaefer L, Behnes CL, Bonrouhi M, Gretz N, et al. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant 2007; 7:527-37; PMID:17229070; http://dx.doi.org/10.1111/j.1600-6143.2006.01654.x.
59. Mohty D, Pibarot P, Després JP, Côté C, Arsenault B, Cartier A, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008; 28:187-93; PMID:17975118; http://dx.doi.org/10.1161/ATVBAHA.107.154989.
60. Derbali H, Bossé Y, Côté N, Pibarot P, Audet A, Pépin A, et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol 2010; 176:2638-45; PMID:20382708; http://dx.doi.org/10.2353/ajpath.2010. 090541.
61. Saito T, Nishida K, Sugiyama H, Yamato M, Maeda N, Okano T, et al. Abnormal keratocytes and stromal inflammation in chronic phase of severe ocular surface diseases with stem cell deficiency. Br J Ophthalmol 2008; 92:404-10; PMID:18211946; http://dx.doi.org/10.1136/bjo.2007.127738.
62. Adapala VJ, Adedokun SA, Considine RV, Ajuwon KM. Acute inflammation plays a limited role in the regulation of adipose tissue COL1A1 protein abundance. J Nutr Biochem 2011; In press; PMID:21775118; http://dx.doi.org/10. 1016/j.jnutbio.2011.02.013.
63. Popovic ZV, Wang S, Papatriantafyllou M, Kaya Z, Porubsky S, Meisner M, et al. The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J Immunol 2011; 187:6217-26; PMID:22095710; http://dx.doi.org/10.4049/jimmunol. 1003478.
64. Kikuchi A, Tomoyasu H, Kido I, Takahashi K, Tanaka A, Nonaka I, et al. Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells. J Neuroimmunol 2000; 106:78-86; PMID:10814785; http://dx.doi.org/10.1016/ S0165-5728(99)00258-1.
65. Sjöberg AP, Manderson GA, Mörgelin M, Day AJ, Heinegård D, Blom AM. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 2009; 46:830-9; PMID:18962898; http://dx.doi.org/10.1016/j.molimm.2008.09.018.
66. Kitaya K, Yasuo T. Dermatan sulfate proteoglycan biglycan as a potential selectin L/CD44 ligand involved in selective recruitment of peripheral blood CD16(-) natural killer cells into human endometrium. J Leukoc Biol 2009; 85:391-400; PMID:19088176; http://dx.doi.org/10.1189/jlb.0908535.
67. Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177:8095-102; PMID:17114484.
68. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11:141-7; PMID:19946272; http://dx.doi.org/10.1038/ni.1828.
69. Wu F, Vij N, Roberts L, Lopez-Briones S, Joyce S, Chakravarti S. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 2007; 282:26409-17; PMID:17616530; http://dx.doi.org/10.1074/jbc.M702402200.
70. Lee S, Bowrin K, Hamad AR, Chakravarti S. Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin. J Biol Chem 2009; 284:23662-9; PMID:19531489; http://dx.doi.org/10. 1074/jbc.M109.026229.
71. Carlson EC, Lin M, Liu CY, Kao WW, Perez VL, Pearlman E. Keratocan and lumican regulate neutrophil infiltration and corneal clarity in lipopolysaccharide-induced keratitis by direct interaction with CXCL1. J Biol Chem 2007; 282:35502-9; PMID:17911102; http://dx.doi.org/10.1074/jbc.M705823200.
72. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci 2005; 46:88-95; PMID:15623759; http://dx.doi.org/10.1167/iovs.04-0833.
73. Lohr K, Sardana H, Lee S, Wu F, Huso DL, Hamad AR, et al. Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis. Inflamm Bowel Dis 2012; 18:143-51; PMID:21484968; http:// dx.doi.org/10.1002/ ibd.21713.